Fairvalue-Calculator Fairvalue-Calculator
EN DE

Voyager Therapeutics, Inc (VYGR) Fair Value & Analysis

Healthcare · US · Market cap $223M

Price$3.68
Fair Value$2.42
Upside-34.2%
Quality95/100
Evidence: Low Range $1.60 – $3.03

Fair value as of: Jun 25, 2026

Analysis

Voyager Therapeutics, Inc (VYGR) currently trades at $3.68, while our model-based Fair Value estimate is $2.42 — implying the stock looks roughly 34.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Voyager Therapeutics, Inc (VYGR) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $2.42 versus a price of $3.68 — about −34% (overvalued). Model-based estimate, not financial advice.
What is the fair value of VYGR?
Our 21-model fair value for Voyager Therapeutics, Inc is $2.42 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.68.
What is the quality score of VYGR?
Voyager Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.